224 related articles for article (PubMed ID: 19178153)
21. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.
Lee DJ; Robinson WE
J Virol; 2004 Jun; 78(11):5835-47. PubMed ID: 15140981
[TBL] [Abstract][Full Text] [Related]
22. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
[TBL] [Abstract][Full Text] [Related]
24. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro.
Reinke RA; Lee DJ; McDougall BR; King PJ; Victoria J; Mao Y; Lei X; Reinecke MG; Robinson WE
Virology; 2004 Sep; 326(2):203-19. PubMed ID: 15302207
[TBL] [Abstract][Full Text] [Related]
25. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
[TBL] [Abstract][Full Text] [Related]
26. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).
Marchand C; Johnson AA; Karki RG; Pais GC; Zhang X; Cowansage K; Patel TA; Nicklaus MC; Burke TR; Pommier Y
Mol Pharmacol; 2003 Sep; 64(3):600-9. PubMed ID: 12920196
[TBL] [Abstract][Full Text] [Related]
27. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
28. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors.
Sato M; Kawakami H; Motomura T; Aramaki H; Matsuda T; Yamashita M; Ito Y; Matsuzaki Y; Yamataka K; Ikeda S; Shinkai H
J Med Chem; 2009 Aug; 52(15):4869-82. PubMed ID: 19719237
[TBL] [Abstract][Full Text] [Related]
29. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
30. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action.
Mazumder A; Neamati N; Sunder S; Schulz J; Pertz H; Eich E; Pommier Y
J Med Chem; 1997 Sep; 40(19):3057-63. PubMed ID: 9301668
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the strand transfer step of HIV-1 integrase by non-natural dinucleotides.
Chi G; Neamati N; Nair V
Bioorg Med Chem Lett; 2004 Oct; 14(19):4815-7. PubMed ID: 15341930
[TBL] [Abstract][Full Text] [Related]
32. Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site.
Du L; Shen L; Yu Z; Chen J; Guo Y; Tang Y; Shen X; Jiang H
ChemMedChem; 2008 Jan; 3(1):173-80. PubMed ID: 17943714
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 integrase inhibitors: 2005-2006 update.
Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
[TBL] [Abstract][Full Text] [Related]
34. HIV integrase inhibitors as therapeutic agents in AIDS.
Nair V; Chi G
Rev Med Virol; 2007; 17(4):277-95. PubMed ID: 17503547
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.
Zawahir Z; Neamati N
Bioorg Med Chem Lett; 2006 Oct; 16(19):5199-202. PubMed ID: 16879966
[TBL] [Abstract][Full Text] [Related]
36. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
[TBL] [Abstract][Full Text] [Related]
37. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
38. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.
Nakahara K; Wakasa-Morimoto C; Kobayashi M; Miki S; Noshi T; Seki T; Kanamori-Koyama M; Kawauchi S; Suyama A; Fujishita T; Yoshinaga T; Garvey EP; Johns BA; Foster SA; Underwood MR; Sato A; Fujiwara T
Antiviral Res; 2009 Feb; 81(2):141-6. PubMed ID: 19027039
[TBL] [Abstract][Full Text] [Related]
39. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
40. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.
Van Laethem K; Schrooten Y; Covens K; Dekeersmaeker N; De Munter P; Van Wijngaerden E; Van Ranst M; Vandamme AM
J Virol Methods; 2008 Nov; 153(2):176-81. PubMed ID: 18706932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
